全身免疫炎症指数在乳腺癌患者预后中预测价值的meta分析  

Meta-analysis of the predictive value of systemic immune inflammatory index in the prognosis of patients with breast cancer

作　　者：谷静静 张维东 陈丹丹[1] 张建国 黄关宏[3] GU Jingjing;ZHANG Weidong;CHEN Dandan;ZHANG Jianguo;HUANG Guanhong(Department of Oncology Radiotherapy,Lianyungang Second People’s Hospital Affiliated Bengbu Medical College,Jiangsu Province,Lianyungang 222000,China;Department of General Surgery,Hangzhou Xixi Hospital,Zhejiang Province,Hangzhou 310000,China;Deputy President’s Office,Lianyungang Second People’s Hospital Affiliated Bengbu Medical College,Jiangsu Province,Lianyungang 222000,China)

机构地区：[1]蚌埠医学院附属连云港市第二人民医院肿瘤放疗科,江苏连云港222000 [2]杭州市西溪医院普外科,浙江杭州310000 [3]蚌埠医学院附属连云港市第二人民医院副院长办公室,江苏连云港222000

出　　处：《中国医药导报》2021年第14期93-97,共5页China Medical Herald

基　　金：江苏省卫生计生委科研课题(H2017040)。

摘　　要：目的研究全身免疫炎症指数(SII)在乳腺癌患者预后中的预测价值。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science数据库,收集2015年1月—2020年7月所有关于SII与乳腺癌患者预后的研究,采用Stata 12.0及Review Manager 5.3软件进行数据分析。结果本研究最终纳入8项研究,包括2642例乳腺癌患者。meta分析结果显示高SII乳腺癌患者肿瘤直径>2.0 cm占比高于低SII乳腺癌患者(OR=1.49,95%CI:1.19~1.85,P=0.0004)。高SII乳腺癌患者淋巴结转移占比高于低SII乳腺癌患者(OR=1.38,95%CI:1.12~1.69,P=0.002)。高SII乳腺癌患者总生存期短于低SII乳腺癌患者(HR=2.06,95%CI:1.55~2.74,P<0.00001)。高SII对乳腺癌术后患者无病生存期短于低SII乳腺癌患者(HR=1.93,95%CI:1.63~2.30,P<0.00001)。结论SII可作为临床预测乳腺癌患者预后的可靠指标。Objective To investigated the predictive value of systemic immune inflammatory index(SII)in the prognosis of patients with breast cancer.Methods PubMed,Cochrane Library,Embase,and Web of Science databases were searched by computer,all the studies on SII and prognosis of patients with breast cancer were collected from January 2015 to July 2020.Stata 12.0 and Review Manager 5.3 software were used for data analysis.Results A total of eight studies were included in this study,including 2642 cases patients with breast cancer.Meta-analysis results showed that the proportion of tumor diameter>2.0 cm in high SII patients with breast cancer was higher than that in low SII patients with breast cancer(OR=1.49,95%CI:1.19-1.85,P=0.0004).The proportion of lymph node metastases in high SII patients with breast cancer was higher than that in low SII patients with breast cancer(OR=1.38,95%CI:1.12-1.69,P=0.002).Overal survival in high SII patients with breast cancer was shorter than those with low SII breast cancer(HR=2.06,95%CI:1.55-2.74,P<0.00001).Distase free survival in high SII patients with breast cancer was shorter than that in low SII patients with breast cancer(HR=1.93,95%CI:1.63-2.30,P<0.00001).Conclusion SII can be used as a reliable indicator to predict the prognosis of patients of breast cancer.

关 键 词：全身免疫炎症指数 乳腺癌 META分析 预后 

分 类 号：R737.9[医药卫生—肿瘤]